Nitric oxide (NO) is a substance produced by vascular endothelium I and formerly termed endothelium-derived relaxing factor (EDRF). It is widely distributed in the body and appears to be an important messenger in the immune, neurological and cardiovascular systems. 2 Although regarded as the endogenous vasodilator, it is also the active substance released from therapeutic nitrovasodilator drugs such as glyceryl trinitrate and sodium nitroprusside. Exogenous nitric oxide is emerging as a valuable therapy for pulmonary hypertension. ' A When administered as a gas it has a selective effect upon the pulmonary circulation, in contrast to intravenously administered nitrovasodilators, because it is inactivated on gaining access to blood where it forms methaemoglobin. The role of NO in vasodilatation and vasodilator therapy is reviewed in this issue. 5 This report illustrates some clinical applications of nitric oxide in the intensive care unit and cardiac catheter laboratory. It has been used approximately once per month at the Royal Children's Hospital, Melbourne, since October 1992. Clinical use was preceded by work in the animal laboratory (unpublished). The method of administration is described in this issue of the journal. 6 At present, NO therapy is experimental in Australia and may only be used for patients in category A of the Special Access Scheme (SAS) of the Therapeutic Goods Administration. These patients must be terminally or seriously ill with life-threatening conditions and they or their guardians must give informed consent. Such consent was obtained from the parents of the children subject to report in this paper.
(A) TREATMENT OF PULMONARY HYPERTENSION AFTER CARDIAC SURGERY Case 1
This one-month-old infant had undergone surgical correction of total anomalous pulmonary venous drainage. The resting mean pulmonary artery pressure (PAP) on the first postoperative day was two-thirds of the mean systemic arterial pressure (SAP) and exceeded mean SAP transiently. The pulmonary hypertension was treated with intravenous glyceryl trinitrate (4 (tg/kg/min) and prostaglandin El (40 ng/kg/min), sedation and hypocarbia (P a C02 ::; 27 mmHg) induced with mechanical ventilation. On one occasion mean PAP remained at 40 mm Hg and was associated with pulseless systemic hypotension (mean 15 mmHg) which necessitated internal cardiac massage. To determine if another pulmonary hypertensive crisis would respond to nitric oxide therapy, a concentration of 40 parts per million (ppm) was administered for one hour. Almost immediately, mean PAP decreased from 31 mmHg and stabilised at 25 mmHg after 20 minutes. The mean SAP decreased simultaneously from 60 to 58 mmHg and the P a 02 increased from 100 to 143 mmHg. The P a C02 remained constant. Right and left atrial pressures remained unaltered at 5 and 7 mmHg respectively. Upon cessation of NO therapy, the mean PAP increased immediately to 30 mmHg but additional life-threatening crises did not occur. The infant required mechanical hyperventilation for five days but weaned successfully.
Case 2
A ten-month-old infant had persistent severe pulmonary hypertension after surgical correction of a ventricular septal defect. The resting mean PAP was 45-50 mmHg but exceeded mean SAP (60 mmHg) during endotracheal suction in spite of heavy sedation, mechanical ventilation (P a C02 36 mmHg) and vasodilator therapy with glyceryl trinitrate (5 {tg/ kg/min) and prostaglandin El (60 ng/kg/min). Inotropic therapy with dopamine (5 {tg/kg/min) and dobutamine (5 {tg/kg/min) were also administered to support biventricular failure. The mean left atrial pressure (LAP) was 17 mmHg and the mean right atrial pressure (RAP) was 21 mmHg. To determine if the pulmonary hypertension was reversible, nitric oxide 60 ppm was administered for 30 minutes. Mean PAP decreased to 38 mmHg, while the mean SAP increased to 66 mmHg, the mean LAP increased to 20 mmHg and the mean RAP decreased to 16 mmHg. The P a 02 increased from 74 mmHg to 121 mmHg, with an F,02 of 0.3, while PaC02 decreased from 41 mmHg to 38 mmHg. Methaemoglobin did not increase from a baseline estimation of 0.1 070 of total haemoglobin. Intravenous vasodilator therapy and mechanical ventilation were provided for a further three days before extubation and eventual recovery.
Case 3
A three-week-old infant had right heart failure and suprasystemic pulmonary hypertension following surgical repair of total anomalous pulmonary venous drainage. The left ventricle was hypoplastic and required inotropic support with dopamine (2-10 {tg/ kg/min) and noradrenaline (0.05-0.07 {tg/kg/min).
Anaesthesia and Intensive Care. Vol. 21, No. 6, December, 1993 Despite heavy sedation, mechanical hyperventilation in 60% oxygen (P a C02 28 mmHg, P a 02 95 mmHg) and infusions of prostaglandin El at 100 ng/kg/min and glyceryl trinitrate at 7 {tg/kg/min, the mean PAP remained at 50-60 mmHg, while the mean SAP was 40-50 mmHg, Endotracheal tube suction promoted further rises in mean PAP. NO therapy was commenced at 40 ppm. Mean PAP declined steadily from 50 mmHg to 29 mmHg within 20 minutes, while mean SAP increased from 42 to 46 mmHg. The P a 02 increased to 193 mmHg, while P a C02 increased to 30 mmHg. NO therapy at 40-80 ppm was continued for 6.5 days. During this time, the mean PAP was controlled at 25-30 mmHg, which was 50% or less of mean SAP, and intravenous vasodilator therapy was ceased. However, the infant could not be weaned from inotropic therapy and died of left ventricular failure. The level of methaemoglobin was 0.7% at the commencement of therapy and 1.6% after six days. Postmortem histological examination of the lungs did not reveal changes, such as damage to the airway epithelium, which may have been attributed to N02 toxicity.
(B) TREATMENT OF PERSISTENT FOETAL CIRCULATION Case 4
A newborn infant presented at three hours of age with cyanosis due to a left-sided diaphragmatic hernia. Institution of mechanical ventilation with an F,02 of 1.0 failed to relieve the cyanosis and was associated with the onset of bradycardia (40 beats/min) and pulselessness. Circulation was restored after two minutes of external cardiac massage and a bolus (0.06 mg/kg) of intravenous adrenaline. Pneumothoraces were detected and initially relieved by needle aspiration. A subsequent radiograph revealed persistent bilateral tension pneumothoraces and a pneumoperitoneum, which were drained with intercostal catheters and a peritoneal catheter. Infusions of dobutamine (20 {tg/kg/min) and adrenaline (0.1 {tg/kg/min) and 25 mllkg of 5% normal serum albumin solution were required to raise the mean arterial blood pressure from 17 to 45 mmHg. Despite these measures, cyanosis persisted. After 25 minutes of mechanical ventilation with an FI02 of 1.0 at a respiratory rate (RR) of 100 breaths/minute, peak inspiratory pressure (PIP) of 50 cmH20, a positive end expiratory pressure (PEEP) of 10 cmH20 and an inspiratory time of 0.3 seconds (mean airway pressure, MAP, 35 CmH20), the post-ductal P a C02 was 16 mmHg and PaOz 37 mmHg. The poor oxygenation was presumed to be a consequence of persistent foetal circulation maintained by pulmonary hypertension associated with pulmonary hypoplasia. The oxygenation index (MAP x FI02/Pa02) was 0.94 and the ventilation index (PaC02 x RR x PIP/WOO) 80. Both indices constitute indications to proceed to extracorporeal membrane oxygenation (ECMO) in our institution. 7 As an alternative to ECMO, NO therapy was commenced at 40 ppm. Cyanosis was relieved within minutes and the Pa02 increased to 106 mmHg. NO was increased to 70 ppm and the P a 02 was measured five minutes later at 458 mmHg. After two hours of NO therapy at 70 ppm the blood methaemoglobin level had increased to 7.8070 from a pre-treatment level of 0.3070. In the meantime mechanical ventilation was reduced to a MAP of 22 cmH20 but FI02 maintained at 1.0. The NO dose was reduced to 20 ppm and after 15 minutes the PaC02 was 25 mmHg and the P a 02 499 mmHg. Forty-five minutes after reduction of NO, the methaemoglobin was still 11.4070. Administration of methylene blue 0.5 mg/kg immediately reduced this to 3.4070 and with a further 0.5 mg/kg to 0.3070. Thereafter the methaemoglobin level remained at 2.0070 or less over the next 52 hours of NO therapy at 20 ppm. Meanwhile, inotropic therapy was withdrawn and mechanical ventilation reduced to provide a MAP of 10 cmH20 with an FI02 of 0.30, which typically yielded a PaC02 of 38 mmHg and a P a 02 140 mmHg. After further reduction in NO therapy to 10 ppm and then 5 ppm it was terminated after a total duration of 62 hours. The diaphragmatic hernia was surgically repaired on day five of life. Clinical and cerebral ultrasound examinations indicated unaffected brain function. The infant was discharged home at one month of age. A 15-year-old with congenital restrIctive cardiomyopathy presented for transplantation. Pulmonary hypertension was known to be present but it was not clear whether it was amenable to medical treatment and hence not clear whether a heart or heart-and-lung transplantation was indicated. At a cardiac catheter study conducted one month earlier under general anaesthesia, the mean PAP was 55 mmHg and was unresponsive to 100070 oxygen, and to hyperventilation. In addition, an infusion of isoprenaline up to 0.1 Ilg/kg/min (sometimes used to treat pulmonary hypertension) caused the mean PAP to rise to 85 mmHg, while the mean SAP decreased from 85 to 80 mmHg and the pulmonary artery occlusion pressure (PAOP) increased from 24 to 28 mmHg. The study was abandoned. Although severe pulmonary hypertension was identified during the study it was not clear if it was amenable to treatment with other vasodilators.
Since a technique to deliver NO therapy to a spontaneously breathing patient had not been developed, the patient was anaesthetised and ventilated via an endotracheal tube. A Swan-Ganz catheter was inserted and a trial conducted with nitric oxide. Baseline recordings were cardiac index 2.4l.minl .m-2 , mean PAP 67 mmHg, PAOP 23 mmHg, mean SAP 86 mmHg and right atrial pressure (RAP) 15 mmHg. The pulmonary vascular resistance index (PVRI) was 1465 dyn.sec.cm -5. m 2 (18.3 wood units.m -2) and systemic vascular resistance index (SVRI) 2364 dyn.sec.cm -5. m -2. Nitric oxide therapy was administered in a stepwise incremental fashion at concentrations of 10, 20, 40 and 80 ppm, each for 15 minutes. Mechanical ventilation and oxygen therapy were unchanged throughout the trial. The P a C02 was maintained at 29-31 mmHg. With NO 10 ppm, the mean PAP decreased to 55 mmHg, the cardiac index to 2.26, the mean SAP to 84 mmHg, the PAOP to 20 mmHg and RAP to 12 mmHg. The PVRI was 1237 dyn.sec.cm 5. m -2 (15.5 wood units. m -2) and SVRI 2545 dyn.sec.cm-5 .m-2 • No further significant reductions were observed with higher concentrations of NO. Methaemoglobin levels remained less than 0.4070. Several hours after cessation of NO therapy an infusion of prostacyclin (PG h) was commenced at a dose of 0.5 ng. kg -I. min -I, with increments to 3 ng. kg -1 .min -I. The mean PAP decreased from 85 to 68 mmHg but was accompanied by a decrease of mean SAP from 86 to 53 mmHg. On cessation of PGh, mean PAP returned to 85 mmHg. Because the PVRI remained high despite the use of NO, this patient was judged to be unsuitable for heart transplantation alone and subsequently received a heart-and-lung transplant.
Case 6
This was a 13-year-old with congenital endocardial fibroelastosis and congestive cardiomyopathy. A cardiac catheter study performed 18 months previously had revealed a PAP of 55/30 mmHg (systolic/diastolic), with a mean of 40 mmHg, a PAOP of 26 mmHg and a left ventricular pressure of 115/5 mmHg (end-diastolic 38 mmHg). An infusion of glyceryl trinitrate up to 3 Ilg/kg/min reduced the mean PAP to 24 mmHg and the PAOP to 18 mmHg. The patient was placed on the heart transplant waiting list. In the interim, however, deterioration occurred. The left ventricular shortening fraction was less than /1naesthesia and Infensive Care, vb/. 21, No. 6, December, 1993 10070 and the exercise-induced ejection fraction 18070. Another cardiac catheter study was undertaken to determine haemodynamic parameters and to assess the response to nitric oxide at the same time. General anaesthesia was induced with thiopentone, fentanyl and pancuronium and maintained with isoflurane. P a C02 was maintained at 37-39 mmHg and P a 02 470-520 mmHg. Baseline recordings were mean PAP 43 mmHg, PAOP 23 mmHg, mean SAP 63 mmHg and cardiac index (Cl) by thermodilution 1.661.min. -1.m-2. Pulmonary vascular resistance index (PVRI) was 963 dyn.sec.cm-5 .m-2 . After 10 minutes of NO at 10-15 ppm the mean PAP was 35 mmHg, PAOP 22 mmHg, mean SAP 65 mmHg and Cl 1.93 l.min. -1.m-2. PVRI was 538 dyn.sec.cm-5 .m-2 . No further improvement was observed with 40 ppm MO. Methaemoglobin levels remained less than 0.5070. On the basis of the response of the pulmonary vasculature to NO, this patient was considered to be suitable for heart transplantation, although NO may be required in the postoperative period.
(D) AUGMENTATION OF PULMONARY BLOOD FLOW Case 7
A one-day-old prematurely born infant (1.44 kg BW) presented with deep cyanosis (P a 02 16-27 mmHg, pulse oximetry, Sp02, 20-40070) in 100070 oxygen. The appearance of the chest X-ray was consistent with pulmonary oligaemia. 2D-echocardiography revealed a tetralogy of Fallot, a ring pulmonary valve and unobstructed mixed anomalous pulmonary venous drainage. The ductus arteriosus was closed. An infusion of prostaglandin El at 5-20 ng.kg-'.min-' failed to reopen the ductus. The mean systemic arterial pressure was maintained at the upper range of normal (40 mmHg), with infusions of dopamine (10 Jlg.kg-'.min-I ) and noradrenaline (0.1 Jlg.kg -'.min -I), with the aim of providing adequate perfusion pressure to the lungs. Despite these measures, increasing metabolic acidosis (base excess -17 mmolll) suggested that oxygen transport was not sufficient. After commencement of NO at 10-15 ppm, the P a 02 was consistently measured at 30-40 mmHg and the Sp02 60-80070, suggesting that pulmonary blood flow had improved. Acidosis abated. Forty hours later the infant was transported with NO therapy to the cardiac catheter laboratory for balloon dilatation of the pulmonary valve. Unfortunately, the procedure did not appear to improve pulmonary blood flow. The transvalvular pressure gradient was subsequently estimated at 40 mmHg. NO therapy was required for a further 3.5 days, after which adequate oxygenation was maintained without drug therapy, presumably because of Anaesthesia and Intensive Care. Vol. 21. No. 6, December, 1993 reduction in pulmonary vascular resistance which occurs over several days after birth. During NO therapy, methaemoglobin levels were 004-0.8070. The infant was successfully extubated at 11 days of age and awaits cardiac surgery.
DISCUSSION
The treatment of pulmonary hypertension is hampered by the lack of an intravenous vasodilator whose activity is confined to the pulmonary vasculature. As these case reports illustrate, beneficial pulmonary effects of currently employed vasodilators are often offset by deleterious effects on the systemic circulation. This problem is avoided with gaseous nitric oxide. Moreover nitric oxide may improve gas exchange, possibly by improving ventilation-perfusion matching.
Several of these case reports illustrate the efficacy of nitric oxide for the treatment of pulmonary hypertension. Nitric oxide in various concentrations has been used by other clinicians to successfully treat pulmonary hypertension in a variety of circumstances. All reports, however, are of single cases or of small cohorts. At 40 ppm in adults 4 and 6-20 ppm in a child, 8 it has been effectively used in the management of idiopathic pulmonary hypertension. Pulmonary hypertension associated with adult respiratory distress syndrome and with chronic obstructive airways disease in adults has been treated with 20-40 ppm. 911 In newborn infants with persistent pulmonary hypertension, NO therapy in concentrations of 6-80 ppm 12.13 produced marked increases in post-ductal oxygenation. In infants and children with pulmonary hypertension secondary to congenital heart disease NO 20-80 ppm, 14 significantly decreased the pressure and resistance of the pulmonary circulation. Pulmonary hypertension after surgical correction of congenital cardiac defects has been amenable to treatment with 6-20 ppm. 1516 Nitric oxide therapy appears to be suitable for the short-term management of pulmonary hypertension in the intensive care unit, cardiac catheter laboratory and operating theatre. It is well suited to administration via endotracheal tube but has also been administered to subjects breathing from a Douglas bag 4 or mask. 14 Gases were scavenged in the latter study.
The decision between heart transplantation alone and heart-and-lung transplantation has major implications. The outcome of the former is considerably better. A decision may be dependent on the degree of pulmonary hypertension and its response to therapy. Nitric oxide therapy enables a simple assessment of the responsiveness of the pulmonary vasculature, without exposure to the risk of systemic hypotension as illustrated in two patients in this report. If pulmonary hypertension is responsive to NO therapy, it implies that not all of pulmonary vascular resistance is fixed and that it may fall with the passage of time after heart transplantation.
In newborn infants with pulmonary hypertension, NO therapy may reduce right to left shunting across the ductus arteriosus and foramen ovale thus increasing oxygenation and decreasing the necessity to achieve pulmonary vasodilatation by hyperventilation. Pulmonary hypertension may cause persistence of foetal circulation in conditions such as meconium aspiration, congenital diaphragmatic hernia, group B streptococcal pneumonia and hyaline membrane disease. Occasionally it may be idiopathic.
A number of congenital cardiac anomalies may cause pulmonary oligaemia without pulmonary hypertension. This is typified by pulmonary atresia in which adequate pulmonary blood flow is dependent upon a patent ductus arteriosus. If the ductus closes, or is absent, as in the infant in this report, pulmonary blood flow is not enough to achieve adequate oxygenation. In this circumstance, dilatation of the pulmonary vasculature with NO may augment flow without diminishing systemic perfusion pressure. Nitric oxide therapy may also prove to be beneficial in patients who have undergone the Fontan operation in which a cavopulmonary connection has been established, thus bypassing the right ventricle. In this circumstance, adequate pulmonary blood flow is dependent upon systemic venous pressure and low pulmonary vascular resistance.
Nitric oxide in therapeutic concentration is reputed to be toxic to the lungs but this has not been demonstrated conclusively.5 There is more concern about nitrogen dioxide (N02) which is formed when NO reacts with oxygen. The amount of N02 generated is determined by the concentrations of both NO and 02 and by the duration of their mixing. An in vitro experiments demonstrated that NO in concentrations of 20 ppm and 1000,70 02 may be permitted to mix for 20-12 minutes before potentially toxic amounts of N02 (5 ppm) are formed. 1-Another study suggested that the critical mixing time for 20 ppm NO and 98% 02 was only five minutes. 18 However, negligible amounts of N02 were detected in the ventilator circuits of three newborns treated with 40 ppm in 95% 02 for up to 15 days. 19 It appears prudent to restrict NO therapy to patients with life-threatening illness, to use the minimum effective concentration in the least possible amount of oxygen and to avoid prolonged mixing before administration. Concentrations of less than 20 ppm appear effective. Levels of methaemoglobin should be regularly monitored to detect accidental overdose. Concentrations of both NO and N02 should be measured in the respiratory circuit with a chemiluminescence apparatus.
At present, the use of NO is experimental. Recently, the author of a journal editorial argued against the widespread adoption of NO therapy without trials. Furthermore, the therapy should be adopted cautiously, particularly for newborn patients with PPHN who frequently require mechanical ventilation with 100% 02 and are thus predisposed to injury with N02. 20 Fortunately, prospective randomised controlled trials are currently being conducted in North America to determine the short-and long-term benefits of NO therapy. In the meantime, the use of NO appears justified in life-threatening circumstances such as nearsystemic pulmonary hypertension or severe pulmonary oligaemia. No other specific pulmonary vasodilator is available.
Thrombolytic therapy with intravenous streptokinase has been shown to improve survival after acute myocardial infarction. 1.2 However, patients who have suspected infarction at the time of an operation would not generally be considered for streptokinase therapy because of their increased risk of surgical bleeding. We present a case of acute myocardial infarction following minor laryngeal surgery under general anaesthesia that was successfully treated with streptokinase.
CASE REPORT
A 65-year-old Polish woman was scheduled for laryngoscopy and possible laryngeal biopsy. Ten months earlier, a TzN o squamous cell carcinoma of the right vocal cord was diagnosed. The patient refused surgery and was treated with radiotherapy. Five months later, she developed progressive upper airway obstruction necessitating a tracheostomy. Two months later, laryngoscopy and biopsy performed under general anaesthesia were negative for tumour and the provisional diagnosis was radionecrosis of the laryngeal cartilages. Immediately prior to the current admission, she experienced throat pain and repeat laryngoscopy was scheduled.
Her only other medical problem was degenerative joint disease and her medications were paracetamol and diflunisal. She had stopped smoking three years earlier. Her mother and sister had heart disease. She spoke minimal English.
On the evening before the procedure, preoperative examination was unremarkable except for the presence of a tracheostomy and obesity. A routine 12-lead electrocardiogram (ECG) was unremarkable. The anaesthetic plan was discussed with her daughter acting as interpreter. An inhalation induction using a tracheostomy tube was discussed. This technique had been used on a previous occasion by this same anaesthetist. The patient agreed to this technique and oral premedication (temazepam 20 mg, metoc!opramide 10 mg) was prescribed.
On the day of surgery, there was a three-hour delay between receiving the premedication and induction of anaesthesia. She arrived in the anaesthetic room crying. After a brief period of reassurance, the tracheal mucosa was sprayed with lignocaine spray via the tracheostomy and a cuffed tracheostomy tube was placed easily. Induction of anaesthesia was achieved with the patient breathing isoflurane and nitrous oxide in oxygen. Laryngoscopy was performed and three superficial biopsies were taken from the right arytenoid area. Operative bleeding was minimal and no haemostatic
